Roche Holding AG Virtual Oncology/SABCS Investor Event Transcript
(audio in progress) please feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Bruno Ashley, Head of Investor Relations.
Bruno, the stage is yours.
Thanks, Henrik. And could I have the first slide, please? So welcome to our eighth and last IR event for 2025, focusing on the Phase III LIDERA results for giredestrant in early ER-positive breast cancer, which just got presented yesterday at the San Antonio Breast Cancer Symposium. As an upfront remark, let me just point out also the event originally had been scheduled for 60 minutes. We have now planned for 90 minutes just to make sure that we have enough time that we can take all your questions, which I'm sure there will be plenty of them.
So let me quickly go through today's agenda. I will start today by providing a quick update on the big picture. I thought this might be needed considering the dense and impactful news flow we experienced in the fourth quarter. And following
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

